Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting approximately 49 10% of reproductive-aged women worldwide. Diagnosis requires two of the following: 50 hyperandrogenism, oligo/anovulation and polycystic ovaries. In addition to reproductive 51 dysfunction, many women with PCOS display metabolic abnormalities associated with 52
4 recent study examining the effects of non-antibiotic drugs on the gut microbiome found that 139 letrozole did not alter growth of ~40 representative gut bacteria (31), this suggests that the 140 differences in gut microbial composition found in the PCOS mouse model are not due to a direct 141 effect of letrozole. Overall, these studies indicate that the gut microbiome of individuals with 142 PCOS differs significantly from healthy individuals and suggest that a microbial imbalance or 143
"dysbiosis" in the gut may contribute to the pathology of PCOS. 144 145
To begin to address whether the gut microbiome contributes to PCOS pathophysiology and if 146 manipulation of the gut microbiome can be used to treat PCOS, we used a co-housing paradigm 147
to determine whether exposure to a healthy gut microbiome protected against development of 148 PCOS metabolic and reproductive phenotypes. Since mice are coprophagic, gut microbes can be 149
readily transferred from one mouse to another through the fecal-oral route. In this study, pubertal 150 female mice were treated with placebo or letrozole and co-housed two per cage for 5 weeks. The 151 groups consisted of co-housed placebo mice, co-housed letrozole mice or a placebo mouse co-152
housed with a letrozole mouse. Overall, co-housing letrozole with placebo mice resulted in 153 substantial improvement in both PCOS metabolic and reproductive phenotypes compared to 154 letrozole mice co-housed together. Furthermore, 16S rRNA gene sequence analysis demonstrated 155 that co-housing letrozole with placebo mice resulted in changes in the beta diversity of the gut 156 microbiome and highlighted specific bacterial genera that may be candidates for pre-or probiotic 157
therapies. Our findings support the idea that there may be a causal link between the gut 158 microbiome and PCOS and that restoration/manipulation of the gut microbiome may be a 159 potential treatment option for PCOS. 160 161
Results and Discussion 162 163
Co-housing letrozole mice with placebo mice resulted in less weight gain and abdominal 164 adiposity 165
To investigate whether exposure to a healthy gut microbiome can protect against the 166 development of a PCOS metabolic and reproductive phenotype, we performed a co-housing 167 study. Female mice were implanted with a placebo or letrozole pellet at 4 weeks of age 168 (n=8/group). The mice were divided into 3 groups and housed two mice per cage resulting in 4 169 groups: co-housed placebo mice (P/P), co-housed letrozole mice (L/L) and co-housed placebo 170
with letrozole mice (P/L and L/P, respectively) ( Fig. 1A) . As shown in Fig. 1B , weight was 171 measured each week during the 5 weeks of treatment. Similarly to previously published studies 172
(27, 30), 2 weeks of letrozole treatment resulted in increased weight compared to placebo 173 treatment that was maintained for the rest of the study (Fig. 1B) . Five weeks of letrozole 174 treatment also increased abdominal adiposity compared to placebo treatment (Fig. 1C ).
175
Interestingly, P/L mice had similar weight gain and abdominal adiposity compared to P/P mice.
176
In contrast, L/P mice gained less weight and exhibited a trend towards less abdominal adiposity 177 compared to L/L mice ( Fig. 1B-C) . It is noteworthy that our previous study showed that letrozole 178 treatment induced weight gain and abdominal adiposity in female mice without a change in food 179 intake or total energy expenditure (30). Since studies have indicated that obesity may be 180
influenced by an increased capacity of the gut microbiome to harvest energy from dietary fiber 181
(21), it would be informative to test whether this occurs in the letrozole-treated gut microbiome 182
and whether exposure to a healthy gut microbiome ameliorated this effect.
184
Co-housing letrozole mice with placebo mice resulted in reduced fasting blood glucose and 185 insulin levels and insulin sensitivity 186
As reported in previous studies (27, 29, 30) , five weeks of letrozole treatment resulted in 187 increased FBG and insulin levels and insulin resistance ( Fig. 1D -F). P/L mice had similar serum 188 glucose and insulin levels and insulin sensitivity to that of the P/P mice while L/P mice had 189
reduced FBG and insulin levels as well as less insulin resistance compared to L/L mice ( Fig. 1D-190 F). Interestingly, the protective effect of co-housing letrozole mice with placebo mice on weight 191 gain only manifested after several weeks of treatment. While our results demonstrated that co-192
housing letrozole mice with placebo mice resulted in protection from changes in FBG and insulin 193 levels and insulin resistance by the end of the study, future studies will be required to ascertain 194
how much time co-housing takes to exert a protective effect on these metabolic factors and what 195 triggers these changes. 196 197 Co-housing letrozole mice with placebo mice resulted in estrous cyclicity 198
In addition to characterizing the effect of co-housing on the PCOS metabolic phenotype, we also 199 assessed the effect on the reproductive axis. As previously published (27, 29) , letrozole treatment 200 resulted in hallmarks of PCOS including elevated testosterone and LH levels and acyclicity in 201 the L/L mice ( Fig. 2A -C). P/L mice did not have changes in testosterone, LH or estrous cyclicity 202 compared to P/P mice ( Fig. 2A-C ). On the other hand, L/P mice had decreased testosterone and 203
LH levels compared to L/L mice ( Fig. 2A-B ). In addition, the L/P mice displayed a full estrous 204 cycle or changes in the morphology of vaginal epithelial cells compared to the constant diestrus 205 exhibited by L/L mice ( Fig. 2C ). 206 207
Co-housing letrozole mice with placebo mice protected ovarian function 208
Consistent with previous reports (27, 29) , the ovaries of letrozole-treated mice (L/L) lacked 209 corpora lutea and displayed cystic follicles and hemorrhagic cysts while the ovaries of P/L mice 210 had a similar morphology to that of P/P mice ( Fig. 3A) . Interestingly, the ovaries of L/P mice 211 lacked cystic follicles and hemorrhagic cysts and contained corpora lutea (Fig. 3A) . The 212
presence of estrous cycles and corpora lutea in the L/P mice suggests that the mice were able to 213 ovulate. Similar to previous reports (29), L/L mice showed a significant increase in both ovarian 214 weight and ovarian mRNA expression levels of follicle-stimulating hormone receptor (Fshr), 215 cytochrome P450 17A1 (Cyp17), and aromatase (Cyp19) compared to P/P mice ( Fig. 3B -E). The 216 ovarian weight and mRNA expression levels in P/L mice mirrored those of the P/P mice ( Fig.  217 3B-E). Compared to L/L mice, L/P mice showed a significant decrease in ovarian weight and 218 mRNA expression levels of Cyp17 while Fshr and Cyp19 mRNA expression levels were 219 comparable to L/L mice ( Fig. 3B -E). Since Cyp17 gene expression is induced by both androgen 220 and insulin (32, 33), it is unsurprising that Cyp17 levels were normalized in L/P mice that had 221 reduced circulating levels of testosterone and insulin. On the other hand, it is not clear why Fshr 222 mRNA levels were increased in both L/L and L/P mice. With regards to aromatase expression, it 223
is notable that letrozole treatment resulted in an increase in mRNA levels that was not altered by 224
co-housing letrozole with placebo mice. This data indicates that suppression of the aromatase 225 enzyme with letrozole treatment in both L/L and L/P mice resulted in a compensatory increase in 226
Cyp19 mRNA and provides indirect evidence that the effect of co-housing did not occur because 227
of decreased letrozole activity in the L/P mice.
229
Gut microbial richness did not correlate with an improved PCOS phenotype 230 6
The overall composition of the gut microbiome from samples collected before placebo and 231 letrozole treatment (time 0) was compared amongst the four co-housing groups (P/P, L/L, P/L 232 and L/P). No significant difference in alpha or beta diversity was observed among groups, 233
indicating that the gut microbiomes were similar prior to treatment (Supplemental Fig. 1 A-B ).
234
Linear regression was used to examine the relationship between alpha diversity of the gut 235 microbiome (Faith's PD) and time. There was a strong positive relationship between alpha 236 diversity and time in P/P mice (r = 0.23) but not L/L mice (r = 0.05) ( Fig. 4A-B ). To account for 237 the repeated measures in this longitudinal study, we also used a linear mixed-effect model to 238
examine the association between microbial diversity and time. This analysis confirmed that there 239 was a significant effect of time on alpha diversity in P/P mice (p = 0.003) but not L/L mice (p = 240 0.2) ( Fig. 4A-B ). These results agree with previous studies that reported lower alpha diversity of 241 the gut microbiome in women with PCOS and rodent PCOS models compared to controls (24, 242 25, 27, 28) . We then investigated whether changes in alpha diversity correlated with improved 243 metabolic and reproductive phenotypes in L/P mice. In contrast to P/P mice, we did not observe 244 a significant effect of time on alpha diversity using linear regression or the linear mixed-effect 245 model in P/L (r = 0.009; p = 1) or L/P (r = 0.08; p = 0.71) mice ( Fig. 4C-D) . These results 246
indicate that the physiological differences between L/L and L/P mice were probably not due to 247 changes in alpha diversity per se but may reflect changes in specific gut microbes. 248 249
Composition of the gut microbiome was altered by co-housing 250
In addition to investigating changes in alpha diversity, we used weighted UniFrac distances to 251 compare the similarity of gut microbial composition (beta diversity) amongst the different 252
groups. While visualization of the UniFrac distances via Principal Coordinate Analysis (PCoA) 253 did not result in distinct clustering, a PERMANOVA test (ADONIS) detected a significant effect 254 of co-housing treatment on the microbial community structure (p=0.001) ( Fig. 5A ). This trend 255
was also observed using unweighted UniFrac (data not shown). Canonical Analysis of Principal 256
Coordinates (CAP) analysis was then used to analyze the microbial composition in response to 257 an a priori defined experimental variable (co-housing treatment). PERMANOVA demonstrated 258 a strong relationship between co-housing treatment and the overall composition of the gut 259 microbiome (p=0.001) ( Fig. 5B ), suggesting that co-housing resulted in a distinct gut microbial 260 community in L/P mice compared to L/L mice. To understand when the gut microbiome 261 diverged, we then compared the fecal samples from the different co-housing treatment groups at 262 each time point ( Fig. 5C -G). By week 2, we observed a significant separation of the bacterial 263 communities in the co-housing treatment groups (p = 0.004) ( Fig. 5D ). This separation occurred 264 at the same time that we observed a protective effect of co-housing on weight gain in L/P mice 265 ( Fig. 1B ), suggesting that changes in the abundance of specific bacteria may result in protection 266 from developing the PCOS phenotype. It is notable that the CAP analysis indicated that co-267
housing also resulted in changes in the gut bacterial community of the P/L mice compared to P/P 268 mice. However, since these changes were not sufficient to alter the metabolic and reproductive 269 phenotypes of the host, these results suggest that the healthy gut microbiome was resistant to any 270 pathological influence from the feces of the letrozole mice.
272
Differentially abundant genera are associated with co-housed letrozole mice 273
Differential abundance of gut bacteria between placebo-and letrozole-treated mice was 274 determined using DESeq2. This approach used a negative binomial regression for modeling 275 count variables and is commonly used for overdispersed data, which is typical of microbiome 276 data (31). DESeq2 identified five bacterial genera that were of higher relative abundance and 277
four bacterial genera that were of lower relative abundance in placebo compared to letrozole 278 mice (Fig. 6A) From the DESeq2 analysis, we then identified three bacterial genera that had shifts in relative 283
abundance corresponding with protection from developing the PCOS phenotype (Fig. 6B-D) . For 284 instance, the relative abundance of Coprobacillus was higher in both P/P and L/P mice compared 285
to L/L mice. Interestingly, all three bacteria have been linked with host metabolism. 286
Coprobacillus was reported to be enriched in healthy individuals compared to obese individuals 287
and was proposed as a novel probiotic due to its association with a healthy gut microbiome (34, 288 35) . Dorea was found to be more abundant in lean than obese individuals (36)and Dorea 289
longicatena was included as a component of the RePOOPulate stool substitute being developed 290 as a treatment for Clostridium difficile (37). Moreover, a higher abundance of Adlercreutzia was 291 previously correlated with obesity (38). Adlercreutzia is also known to convert soy isoflavonoids 292
to non-steroidal estrogens (equol) and was overrepresented in the guts of individuals who eat a 293 soy diet (39).
295
In summary, our study demonstrated that co-housing letrozole mice with placebo mice resulted 296
in protection from developing PCOS metabolic and reproductive phenotypes. In particular, 297
exposure to a healthy gut microbiome resulted in letrozole-treated mice with body weight, FBG 298
and insulin levels, and insulin resistance similar to placebo mice (Fig. 1) . Surprisingly, co-299
housing letrozole-treated mice with healthy mice also resulted in letrozole-treated mice with 300 testosterone and LH levels, estrous cycling and ovarian morphology similar to placebo mice 301 ( Fig. 2-3 America) for 5 weeks. For the co-housing paradigm, mice were housed two per cage: two 321 placebo mice, two letrozole mice or one placebo and one letrozole mouse. All animal procedures 322 in this study were approved by the University of California, San Diego Institutional Animal Care 323
and Use Committee (protocol number S14011). 324 325
Analysis of Reproductive Phenotype 326
Mice were weighed weekly. Estrous cycle stage was determined from the predominant cell type 327
in vaginal epithelial smears obtained during weeks 4-5 of treatment as previously described (29).
328
At the end of the experiment, ovaries were dissected, weighed, fixed in 4% paraformaldehyde, 329
paraffin-embedded, sectioned at 10 μm and stained with hematoxylin and eosin (Zyagen). Serum 330 testosterone and LH levels were measured using a mouse ELISA (range 10-800 ng/dL) and a 331 radioimmunoassay (range 0.04-75 ng/mL), by the University of Virginia Center for Research in 332
Reproduction Ligand Assay and Analysis Core Facility. 333 334
Analysis of Metabolic Phenotype 335
After 5 weeks of treatment, mice were fasted for 5 hours and blood from the tail vein was 336 collected to measure fasting insulin levels. Blood glucose was measured using a handheld 337 glucometer (One Touch UltraMini, LifeScan, Inc) and an intraperitoneal ( on an Illumina MiSeq as previously described (27). 366
16S rRNA Gene Sequence Analysis 367 9
Raw sequences were imported into QIIME 2 (version 2018.4) using the q2-tools-import script 368
and sequences were demultiplexed using the q2-demux emp-single script. This resulted in 7.3 369 million sequences with an average of 36,000 sequences per sample. The 16S rRNA sequences 370 generated in this study were deposited into the European Nucleotide Archive (Study Accession 371
Number PRJEB29583). DADA2 software was used to obtain a set of Observed Sequence 372
Variants (SVs) (42). Based on the quality scores, the forward reads were truncated at position 373 240 using the q2-dada2-denoise script. Taxonomy was assigned using a pre-trained Naïve Bayes 374 classifier (Greengenes 13_8 99% operational taxonomic units) and the q2-feature-classifier 375 plugin (43). In total, 318 SVs were identified from 186 fecal pellets. The resulting SVs were then 376 aligned using MAFFT (44) and a phylogenetic tree was built using FastTree (45). Taxonomic 377 distributions of the samples were calculated using the q2-taxa-barplot script. Alpha and beta 378 diversity metrics were computed using the q2-diversity core-metrics script at a rarefied sampling 379 depth of 1250. Rarefaction resulted in the removal of one sample that had ~400 sequences. The 380 alpha diversity metric, Faith's Phylogenetic Diversity (PD), was used to measure phylogenetic 381 biodiversity by calculating the total branch lengths on a phylogenetic tree of all members in a 382
community (46) Reproduction and Infertility (P50 HD012303). P.J.T. was also funded by the UCSD Microbial 417
Sciences the weighted UniFrac distances indicated that co-housing had a strong influence on the gut 597 microbial community (p=0.001). Constrained analysis of principal coordinates (CAP) of 598
weighted UniFrac distances further illustrated the relationship between beta diversity and post-599 treatment with a significant effect of constraining the data based on co-housing treatment group 600 (p=0.001) (B). Samples from the different co-housing groups were then compared at each time 601 point (C-G). Permutational analysis of variance of the weighted UniFrac distances was done for 602 each time point. 603 604 Fig. 6 . Specific bacterial genera were associated with improvement of the PCOS phenotype 605 during co-housing. 606
The co-housing study included 3 groups of female mice housed 2 per cage: co-housed placebo 607 mice (P/P), co-housed letrozole mice (L/L), and co-housed placebo with letrozole mice (P/L and 608 L/P, respectively). Results from the DESeq2 differential abundance analysis were expressed as 609 log2 fold change for the comparison of L/L mice and P/P mice (A). Positive log2 fold changes 610
represent bacterial genera increased in P/P mice relative to L/L mice while negative changes 611
represent bacterial general increased in L/L mice relative to P/P mice. * p<0.05, ** p<0.01, *** 612 p<0.001. Of the bacteria identified with the DESeq2 analysis, three bacterial genera had changes 613
in relative abundance associated with co-housing letrozole mice with placebo mice (B-D). LM: r = 0.23, p = 0.0003 LME: p = 0.003 LM: r = 0.05, p = 0.07 LME: p = 0.20 LM: r = 0.009, p = 0.23 LME: p = 1 LM: r = 0.08, p = 0.03 LME: p = 0.71 -2 - 
